(VIANEWS) – Fortress Biotech (FBIOP), Pfizer (PFE), ONE Gas (OGS) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| Fortress Biotech (FBIOP) | 17.39% | 2023-12-14 07:41:06 |
| Pfizer (PFE) | 5.92% | 2023-12-28 12:57:55 |
| ONE Gas (OGS) | 4% | 2023-12-28 12:57:38 |
| State Street Corporation (STT) | 3.58% | 2023-12-28 12:22:14 |
| McDonald’s (MCD) | 2.29% | 2023-12-28 12:23:04 |
Almost 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. Fortress Biotech (FBIOP) – Dividend Yield: 17.39%
Fortress Biotech’s last close was $13.48, 33.76% below its 52-week high of $20.35. Intraday change was -0.15%.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.
Earnings Per Share
As for profitability, Fortress Biotech has a trailing twelve months EPS of $-0.86.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -414.52%.
More news about Fortress Biotech.
2. Pfizer (PFE) – Dividend Yield: 5.92%
Pfizer’s last close was $28.79, 44.56% under its 52-week high of $51.93. Intraday change was 0.75%.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Pfizer has a trailing twelve months EPS of $1.83.
PE Ratio
Pfizer has a trailing twelve months price to earnings ratio of 15.75. Meaning, the purchaser of the share is investing $15.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Pfizer’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Pfizer’s EBITDA is 2.62.
Moving Average
Pfizer’s value is under its 50-day moving average of $29.79 and way under its 200-day moving average of $35.37.
Sales Growth
Pfizer’s sales growth is negative 41% for the ongoing quarter and negative 10.3% for the next.
Previous days news about Pfizer
- Pfizer (pfe) surpasses market returns: some facts worth knowing. According to Zacks on Wednesday, 27 December, "From a valuation perspective, Pfizer is currently exchanging hands at a Forward P/E ratio of 18.57. ", "In the latest trading session, Pfizer (PFE Quick QuotePFE – Free Report) closed at $28.61, marking a +0.7% move from the previous day. "
More news about Pfizer.
3. ONE Gas (OGS) – Dividend Yield: 4%
ONE Gas’s last close was $64.27, 23.72% under its 52-week high of $84.26. Intraday change was 0.03%.
ONE Gas, Inc., together with its subsidiaries, operates as a regulated natural gas distribution company in the United States. The company provides natural gas distribution services to approximately 2.3 million customers in Oklahoma, Kansas, and Texas. It serves residential, commercial, and transportation customers. ONE Gas, Inc. was founded in 1906 and is headquartered in Tulsa, Oklahoma.
Earnings Per Share
As for profitability, ONE Gas has a trailing twelve months EPS of $4.1.
PE Ratio
ONE Gas has a trailing twelve months price to earnings ratio of 15.7. Meaning, the purchaser of the share is investing $15.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.94%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONE Gas’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
ONE Gas’s EBITDA is 2.55.
Volume
Today’s last reported volume for ONE Gas is 57713 which is 89.24% below its average volume of 536479.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 13, 2023, the estimated forward annual dividend rate is 2.6 and the estimated forward annual dividend yield is 4%.
More news about ONE Gas.
4. State Street Corporation (STT) – Dividend Yield: 3.58%
State Street Corporation’s last close was $78.42, 17.23% below its 52-week high of $94.74. Intraday change was 0.42%.
State Street Corporation, through its subsidiaries, provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, including custody, accounting, regulatory reporting, investor, and performance and analytics; middle office products, such as IBOR, transaction management, loans, cash, derivatives and collateral, record keeping, and client reporting and investment analytics; foreign exchange, and brokerage and other trading services; securities finance and enhanced custody products; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; performance, risk, and compliance analytics; and financial data management to support institutional investors. It also engages in the provision of portfolio management and risk analytics, as well as trading and post-trade settlement services with integrated compliance and managed data. In addition, the company offers investment management strategies and products, such as core and enhanced indexing, multi-asset strategies, active quantitative and fundamental active capabilities, and alternative investment strategies. Further, it provides services and solutions, including environmental, social, and governance investing; defined benefit and defined contribution; and global fiduciary solutions, as well as exchange-traded funds under the SPDR ETF brand. The company provides its products and services to mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments, and investment managers. State Street Corporation was founded in 1792 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, State Street Corporation has a trailing twelve months EPS of $6.88.
PE Ratio
State Street Corporation has a trailing twelve months price to earnings ratio of 11.38. Meaning, the purchaser of the share is investing $11.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.01%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 9.1%, now sitting on 12.02B for the twelve trailing months.
More news about State Street Corporation.
5. McDonald’s (MCD) – Dividend Yield: 2.29%
McDonald’s’s last close was $295.84, 1.17% under its 52-week high of $299.35. Intraday change was 0.25%.
McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. The company's restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, fries, salads, shakes, frozen desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including muffins, Sausages, biscuit and bagel sandwiches, oatmeal, hash browns, breakfast burritos and hotcakes. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, McDonald’s has a trailing twelve months EPS of $11.34.
PE Ratio
McDonald’s has a trailing twelve months price to earnings ratio of 26.04. Meaning, the purchaser of the share is investing $26.04 for every dollar of annual earnings.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14%, now sitting on 25.01B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
McDonald’s’s EBITDA is 10.31.
Volatility
McDonald’s’s last week, last month’s, and last quarter’s current intraday variation average was 0.49%, 0.26%, and 0.76%.
McDonald’s’s highest amplitude of average volatility was 0.49% (last week), 0.69% (last month), and 0.76% (last quarter).
More news about McDonald’s.
